AVTX insider grant: 40,200 options exercisable through 2035

Rhea-AI Filing Summary

Avalo Therapeutics director Kevin Robert Lind was granted a stock option on 10/01/2025 to buy 40,200 shares of common stock at an exercise price of $12.96. The option becomes exercisable in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the director's continued service. The option expires on 10/01/2035 and the reporting Form 4 was filed on 10/02/2025 by power of attorney. The grant is reported as a direct holding and shows 40,200 shares underlying the derivative security following the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lind Kevin Robert

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,200 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lind Kevin Robert

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.96	10/01/2025		A		40,200		(1)	10/01/2035	Common Stock	40,200	$0	40,200	D

Explanation of Responses:

1. The stock option vests in three substantially equal installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date.

	/s/ Donald R. Reynolds, by Power of Attorney	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Avalo Therapeutics insider Kevin Robert Lind report on Form 4 (AVTX)?

The Form 4 reports a grant on 10/01/2025 of a stock option to purchase 40,200 shares at an exercise price of $12.96.

When does the option granted to Kevin Robert Lind become exercisable and when does it expire?

The option vests in three substantially equal installments on the first, second and third anniversaries of the 10/01/2025 grant date and expires on 10/01/2035.

How many shares does Kevin Robert Lind beneficially own after the reported transaction?

Following the reported transaction, the Form 4 shows beneficial ownership of 40,200 underlying shares tied to the option.

How was the Form 4 filed and who signed it?

The Form 4 was signed by Donald R. Reynolds by power of attorney on 10/02/2025.

Is the reporting person an officer, director, or 10% owner of Avalo Therapeutics?

The form indicates the reporting person is a Director of Avalo Therapeutics and not marked as a 10% owner.